Oncology Commons^™

Pemetrexed With Or Without Matuzumab As Second-Line Treatment For Patients With Stage Iiib/Iv Non-Small Cell Lung Cancer, Joan Schiller, Joachim Von Pawel, Philipp Schütt, Rafat Ansari, Michael Bijoy Thomas, Mansoor Saleh, Robert D. Mccroskey, Wolfgang Pfeife, Thomas Marsland, Goetz Kloecker

Haematology and Oncology, East Africa

Introduction: This randomized phase II study investigated pemetrexed in combination with the epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab compared with pemetrexed alone as second-line therapy for patients with advanced non-small cell lung cancer.

Methods: Patients received pemetrexed 500 mg/m2 every 3 weeks either alone (n = 50) or in combination with matuzumab at either 800 mg weekly (n = 51) or 1600 mg every 3 weeks (n = 47). The primary end point was objective response, as assessed by an independent review committee.

Results: Tumor EGFR expression was detected in 87% of randomized patients. The objective response rate …

Acute Lymphoblastic Leukemia Subsequent To Temozolomide Use In A 26-Year-Old Man: A Case Report., Asim Jamal Shaikh, Nehal Masood

Section of Haematology/Oncology

Introduction: We report the development of acute lymphoblastic leukemia in a Patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents, the leukemogenic potential of temozolomide is considered to be very low, and very rarely are such cases reported. Case Presentation: A 26-year-old Pakistani man who was treated for glioblastoma with temozolomide in an adjuvant setting was diagnosed to have acute lymphoblastic leukemia one year after stopping temozolomide. Conclusion: Temozolomide is a highly active agent, used in the management of high-grade brain neoplasms. The agent is generally regarded to be safe, …